TABLE 4.
Final population PK models for ceftazidime, avibactam, and aztreonama
| Final ceftazidime PopPK model |
Final avibactam PopPK model |
Final aztreonam PopPK model |
||||||
|---|---|---|---|---|---|---|---|---|
| Parameter | Estimate | RSE (%) | Parameter | Estimate | RSE (%) | Parameter | Estimate | RSE (%) |
| CLR (L/h) | 5.69 | 3.8 | CLR (L/h) | 12.20 | 2.7 | CLR (L/h) | 4.79 | 3.3 |
| V1 (L) | 10.50 | 4.0 | V1 (L) | 12.40 | 4.5 | V1 (L) | 3.77 | 37.9 |
| Q (L/h) | 6.93 | 10.3 | Q (L/h) | 7.81 | 9.3 | Q (L/h) | 28.7 | 24.3 |
| V2 (L) | 8.40 | 4.0 | V2 (L) | 9.06 | 4.9 | V2 (L) | 9.87 | 13.7 |
| CLNR (L/h) | 2.89 | 8.6 | CLNR (L/h) | 1.39 | 25.5% | CLNR (L/h) | 2.66 | 5.8% |
| θ(CLR-LBW) | 0.0146 | 17.5 | θ(V1-LBW) | 0.0194 | 22.9% | θ(CLR-CLcr) | 0.622 | 20.4% |
| θ(V1-LBW) | 0.0166 | 22.8 | θ(Q-LBW) | 0.021 | 42.2% | θ(V1-BSA) | 4.11 | 34.5% |
| θ(Q-LBW) | 1.42 | 32.5 | θ(V2-LBW) | 0.0214 | 23.0% | θ(CLNR-CZA/ATM) | –0.391 | 14.0% |
| θ(V2-LBW) | 0.0254 | 1.01 | θ(CLR-CLcr) | 0.00453 | 21.0% | |||
| θ(CLNR-CZA/ATM) | –0.905 | 6.3 | θ(Q-CI) | –0.407 | 20.3% | |||
| θ(CLR-CZA/ATM) | 1.39 | 4.9 | ||||||
| θ(CLR-SCR) | –0.494 | 25.3 | ||||||
| θ(Q-CI) | –0.396 | 21.8 | ||||||
V1, the volume of the central compartment; Q, intercompartmental clearance; V2, volume of the peripheral compartment; CLR, renal clearance; CLNR, nonrenal clearance; RSE, relative standard error; IIV/BSV, interindividual variability/between-subject variability; CV, coefficient of variation (%); BMI, body mass index; LBM, lean body weight; BSA, body mass index; SCR, serum creatinine; CLCR, creatinine clearance; CZA/ATM, coadministration of ceftazidime/avibactam with aztreonam; CI, continuous infusion.
IIV/BSV V2 was fixed to 0 in the final model; the parameter estimate was near its boundary with high shrinkage of 99%.
IIV/BSV V1 was fixed to 0 in the final model, as the parameter estimate was near its boundary (shrinkage, 99%).